Guerra-Márquez A

Language: Spanish
References: 18
Page: 120-122
PDF size: 36.90 Kb.

Text Extraction

No abstract

REFERENCES

1. Departament of Health and Human Services, Food and Drug Administration. Recommendations to decrease the risk of transmitting acquired immunodeficiency syndrome (AIDS) from blood donors.March 24,1983.

2. Pindyck J, Waldman A, Olesko W, et al. Prevalence of viral antibodies and leukocyte abnormalities among blood donors considering themselves at risk of exposure to AIDS. Ann NY Acad Sci 1984;437:472-84.

3. Pindyck J, Waldman A, Zang E, Oleszko W, Lowy M, Bianco C. Measures to decrease the risk of acquired immunodeficiency syndrome transmission by blood transfusion. Transfusion 1985;25:3-9.

4. Kalish RI, Cable RG, Roberts SC. Voluntary deferral of blood donations and HTLV-III positivity (letter). N Engl J Med 1986;314:1115-6.

5. Departament of Health and Human Services, Food and Drug Administration. Additional recommendations for reducing further the number of units of blood and plasma donated for transfusion or for further manufacture by persons at increased risk of HTLVIII/ LAV infection. October 30,1986.

6. Loiacono BR, Carter GR, Carter CS, Leitman SF, Klein HG. Efficacy of various methods of confidential unit exclution in identifying potentially infectious blood donations. Transfusion 1989;29(9):823-6.

7. Soloway HB. Confidential unit exclution (CUE) is just another test (letter). Transfusion 1991;31:286-7.

8. Busch MP, Perkins HA, Holland P, Petersen L. The CUE debate (continued): on surrogate tests and surrogate endpoints (letter). Transfusion 1991;31:869.

9. Petersen LR, Busch MP. Confidential unit exclution: how should it be evaluated? (letter). Transfusion 1991;31:869-70.

10. Chambers La, Volpp JL, Page PG et al. Failure of self deferral of high risk anti- HTLV-III positive volunteer blood donors (abstract). Transfusion 1986;26:591.

11. Revised recommendations for the prevention of human immunodeficiency virus (HIV) transmission by blood and blood products. Memorandum to blood stablishments. Bethesda: Food and Drug Administration, Public Health Service, US Dept of Health and Human Services. December 1990.

12. Silvergleid AJ, Leparc GF, Schmidt PJ. Impact of explicit questions about high-risk activities on donor attitudes and donor referral patterns. Results in two community blood centers. Transfusion 1989;29:362-4.

13. Johnson ES, Doll LS, Satten GA et al. Direct oral questions to blood donors: the impact on screnning for human immunodeficiency virus. Transfusion 1994;34:769-74.

14. Korelitz JJ, Williams AE, Busch MP, Zuck TF, Ownby HE, Matijas LJ, Wright DJ. Demographic characteristics and prevalence of serologic markers among donors who use the confidential unit exclution process: the Retrovirus Epidemiology Donor Study. Transfusion 1994;34:870-6.

15. Pichardo MMJ, Malagón MA, Marín AO, López CP, Alvarado MC, Guerra MA. Estudio comparativo de frecuencia de seroconversión de donadores de sangre que se autoexcluyen. IV Reunión Regional de Investigación Médica Región La Raza, Toluca, Estado de México 1998. Resúmen 98, pág. 72-3.

16. Prohaska T, Albrecht G, Levy J, Sugrue N, Kim J. Determinants of self-perceived risk of AIDS. Journal of Health on Social Behavior 1990;31:384-94.

17. Guerra MA, Malagón MA, Alvarado MC, Berges GA, Pichardo MMJ. Risk factors for blood donors with serological markers for the human immunodeficiency virus. 12th World AIDS Conference, Geneva 1998 Abstract 23256.

18. Lefrére JJ, Elghouzzi MH, Salpétrier J, Duc A, Dupuy-Montbrun MC. Interviews of individuals diagnosed as antihuman immunodeficiency virus-positive through the screening of blood donations in the Paris area from 1991 to 1994: reflections on the selection of blood donors. Transfusion 1996;36:124-27.